The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Abstract
There are no treatments in clinical practice known to mitigate the neurobiological processes that convert a healthy brain into an epileptic one, a phenomenon known as epileptogenesis. Downregulation of protein phosphatase 2A, a protein that causes the hyperphosphorylation of tau, is implicated in neurodegenerative diseases commonly associated with epilepsy, such as Alzheimer's disease and traumatic brain injury. Here we used the protein phosphatase 2A activator sodium selenate to investigate the role of protein phosphatase 2A in three different rat models of epileptogenesis: amygdala kindling, post-kainic acid status epilepticus, and post-traumatic epilepsy. Protein phosphatase 2A activity was decreased, and tau phosphorylation increased, in epileptogenic brain regions in all three models. Continuous sodium selenate treatment mitigated epileptogenesis and prevented the biochemical abnormalities, effects which persisted after drug withdrawal. Our studies indicate that limbic epileptogenesis is associated with downregulation of protein phosphatase 2A and the hyperphosphorylation of tau, and that targeting this mechanism with sodium selenate is a potential anti-epileptogenic therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal models of TLE, tau hyperphosphorylation is observed in relevant brain regions, including the amygdala, hippocampus, and cortex, following chemical and electrical amygdala kindling (Jones et al., 2012; Liu et al., 2016; Alves et al., 2019).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Liu et al., 2016
In the citing paper
“The antiepileptic effects of sodium selenate persist following drug washout in animal TBI models (Liu et al., 2016), highlighting a potential disease-modifying effect of PP2A upregulation by sodium selenate during epileptogenesis when applied in early PTE disease stage.”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Liu et al., 2016
In the citing paper
“However, long-lasting phosphatase downregulation ultimately occurs, as evidenced by decreased PP2A activity paired with increased p-tau levels observed in epileptogenic brain regions following post-kainic acid status epilepticus, amygdala kindling, and fluid percussion injury in rats (Liu et al., 2016).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Liu et al., 2016
In the citing paper
“Sodium selenate is a specific agonist for PP2A expressing the regulatory B subunit, an essential subunit for tau dephosphorylation by PP2A (Jones et al., 2012; Liu et al., 2016), and shows promise as a potential antiepileptic treatment option.”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Liu et al., 2016
In the citing paper
“Sodium selenate treatment attenuates seizure activity and tau hyperphosphorylation and accumulation following administration of pentylenetetrazol or kainic acid as well as in the TLE model of amygdala kindling and the fluid percussion injury model of PTE (Jones et al., 2012; Liu et al., 2016).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Liu et al., 2016
Citations
Cites
Abràmoff, M. D., Magalhães, P. J., & Ram, S. J. (2004) · Utrecht University Repository (Utrecht University) · Cited by 11,816
Spin Diffusion Measurements: Spin Echoes in the Presence of a Time-Dependent Field Gradient
Stejskal, E. O., & Tanner, J. E. (1965) · The Journal of Chemical Physics · doi:10.1063/1.1695690 · Cited by 8,239
Fisher, R. S., Boas, W. V. E., Blume, W. T., Elger, C. E., Genton, P., Lee, P., & Engel, J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.66104.x · Cited by 3,678
Beghi, E., Berg, A. T., Carpio, A., Forsgren, L., Hesdorffer, D. C., Hauser, W. A., Malmgren, K., Shinnar, S., Temkin, N. R., Thurman, D. J., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00273_1.x · Cited by 2,301
Janssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,927
Automatic quantitation of localized in vivo1H spectra with LCModel
Provencher, S. W. (2001) · NMR in Biomedicine · doi:10.1002/nbm.698 · Cited by 1,640
Serine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Multinuclear NMR Studies on the Energy Metabolism of Glial and Neuronal Cells
Brand, A., Richter‐Landsberg, C., & Leibfritz, D. (1994) · Developmental Neuroscience · doi:10.1159/000111347 · Cited by 889
Kindling and status epilepticus models of epilepsy: rewiring the brain
Morimoto, K., Fahnestock, M. L., & Racine, R. J. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.03.009 · Cited by 854
Research works printed but not linked: 2
- Abramoff, 2004, Image processing with Image J, Biophoton Int, 11, 36
- 10.1042/bj3530417 · DOI
Cited by
Sorted by citations
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Tau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management
Galovic, M., Ferreira‐Atuesta, C., Abraira, L., Döhler, N., Sinka, L., Brigo, F., Bentes, C. C., Zelano, J., & Koepp, M. J. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00837-7 · Cited by 202
Gourmaud, S., Shou, H., Irwin, D. J., Sansalone, K., Jacobs, L. M., Lucas, T. H., Marsh, E. D., Davis, K. A., Jensen, F. E., & Talos, D. M. (2020) · Brain · doi:10.1093/brain/awz381 · Cited by 155
KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy
Shekh‐Ahmad, T., Eckel, R., Naidu, S. D., Higgins, M., Yamamoto, M. P., Dinkova‐Kostova, A. T., Kovac, S., Abramov, A. Y., & Walker, M. C. (2018) · Brain · doi:10.1093/brain/awy071 · Cited by 150
Metadata
- Authors
- Liu, S.-J., Zheng, P., Wright, D. K., Dezsi, G., Braine, E., Nguyen, T., Corcoran, N. M., Johnston, L. A., Hovens, C. M., Mayo, J. N., Hudson, M., Shultz, S. R., Jones, N. C., & O’Brien, T. J.
- Affiliations
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-11
- Volume
- 139
- Issue
- 7
- Pages
- 1919-1938
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2412978786
- Cited by
- 127
- References
- 57
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 18 · 2020: 11 · 2019: 20 · 2018: 11 · 2017: 11 · 2016: 1
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- sodium selenate, epileptogenesis, protein phosphatase 2A, tau hyperphosphorylation, acquired epilepsy, amygdala kindling, status epilepticus, post-traumatic epilepsy, limbic epilepsy, drug withdrawal
- MeSH terms
- Brain Injuries, Traumatic, Animals, Anticonvulsants, Brain, Disease Models, Animal, Electroencephalography, Epilepsy, Kainic Acid, Kindling, Neurologic, Magnetic Resonance Imaging, Male, Phosphorylation, tau Proteins, Rats, Wistar, Excitatory Amino Acid Agonists, Rats, Protein Phosphatase 2, Selenic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
